Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies.

  • Castro C
  • Im H
  • Le C
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Our increased understanding of ovarian cancer's blueprints (mediated by DNA and RNA) and behavior (mediated by proteins) points to wide differences across patients that cannot be depicted by histology alone. Conventional diagnosis usually entails an adequate tissue biopsy, which limits serial testing. There is thus a motivation to shift towards easier to obtain clinical samples (e.g., ascites or blood). In response, investigators are increasingly leveraging alternative circulating biomarkers in blood or proximal fluids and harnessing novel profiling platforms to help explore treatment-related effects on such biomarkers in serial fashion. In this review, we discuss how new nanotechnologies we developed intersect with alternative ovarian cancer biomarkers for improved understanding of metastases and therapeutic response.

Author-supplied keywords

  • ascites
  • biomarkers
  • cells
  • circulating tumor
  • exosomes
  • microfluidics
  • nanotechnology
  • nuclear magnetic
  • ovarian cancer
  • resonance
  • smart or targeted therapies
  • the promise of
  • unique to specific

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Cesar M Castro

  • Hyungsoon Im

  • Christine Le

  • Hakho Lee

  • Ralph Weissleder

  • Michael J Birrer

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free